
    
      During this study, patients will receive infusions of pembrolizumab with radiotherapy
      (palliative QUADSHOT regimen). The patient will receive treatment of pembrolizumab once every
      3 weeks and palliative "QUAD SHOT" radiotherapy every 4 weeks. These 28 day period of time is
      called a cycle. The cycle will be repeated 3 times. Each cycle is numbered in order. The
      patient will be treated for up to 3 cycles followed by pembrolizumab single drug until
      unacceptable toxicity or tumor progression.

      The patient will also complete a survey.

      Total duration of the study is up to two years.
    
  